Parameters | Treatment group (n = 177) | Control group (n = 180) | P value |
---|---|---|---|
sex(Male/Female) | 54/123 | 63/117 | 0.366 |
Age(year) | 39.70 ± 12.81 | 38.99 ± 11.56 | 0.654 |
weight | 59.74 ± 9.22 | 60.94 ± 10.07 | 0.301 |
Course (months) | 95.76 ± 86.82 | 91.61 ± 81.87 | 0.695 |
Migraine days | 4.02 ± 2.16 | 4.09 ± 1.73 | 0.181 |
Migraine attacks | 3.37 ± 1.16 | 3.53 ± 1.11 | 0.099 |
Total duration(h) | 31.87 ± 36.47 | 30.26 ± 27.90 | 0.936 |
VAS scores | 5.63 ± 1.31 | 5.63 ± 1.27 | 0.661 |
Analgesic consumption(times) | 1.34 ± 1.66 | 1.35 ± 1.87 | 0.726 |
Total scores of PRO | 34.34 ± 5.82 | 34.94 ± 5.63 | 0.189 |
Headache | 12.50 ± 1.983 | 12.71 ± 1.89 | 0.237 |
Somatization symptoms | 10.53 ± 2.47 | 10.50 ± 2.51 | 0.910 |
Psychological state | 4.71 ± 1.46 | 4.89 ± 1.49 | 0.195 |
Functional status | 5.77 ± 1.51 | 5.92 ± 1.49 | 0.348 |
PF | 92.91 ± 7.07 | 92.97 ± 8.08 | 0.527 |
RP | 63.07 ± 37.51 | 64.56 ± 37.56 | 0.257 |
BP | 53.71 ± 13.78 | 52.97 ± 13.98 | 0.636 |
GH | 60.91 ± 16.93 | 61.86 ± 17.19 | 0.531 |
VT | 72.52 ± 13.87 | 72.31 ± 14.71 | 0.781 |
SF | 77.07 ± 13.18 | 75.24 ± 14.56 | 0.630 |
RE | 70.42 ± 36.22 | 64.13 ± 39.73 | 0.371 |
MH | 72.93 ± 14.41 | 71.39 ± 15.87 | 0.766 |
MCS | 73.23 ± 14.83 | 70.77 ± 17.60 | 0.620 |
PCS | 67.65 ± 14.31 | 68.09 ± 14.68 | 0.596 |